menu
    • menu
    [{"orgOrder":0,"company":"IDT Biologika GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"MVA-SARS-2-S vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"IDT Biologika GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"IDT Biologika GmbH \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"IDT Biologika GmbH \/ Not Applicable"},{"orgOrder":0,"company":"IDT Biologika GmbH","sponsor":"IDT Biologika GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"MVA-SARS-2-S vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"IDT Biologika GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"IDT Biologika GmbH \/ IDT biologika","highestDevelopmentStatusID":"6","companyTruncated":"IDT Biologika GmbH \/ IDT biologika"},{"orgOrder":0,"company":"IDT Biologika GmbH","sponsor":"Valneva","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Termination","leadProduct":"Aluminium Hydroxide","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"IDT Biologika GmbH","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.040000000000000001,"dosageForm":"Injection","sponsorNew":"IDT Biologika GmbH \/ Valneva","highestDevelopmentStatusID":"12","companyTruncated":"IDT Biologika GmbH \/ Valneva"}]

    Find Clinical Drug Pipeline Developments & Deals by IDT Biologika GmbH

    Menu

    IDT Biologika GmbH

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            IDT Biologika GmbH

                            Germany arrow
                            Fi Europe 2024
                            Not Confirmed

                            IDT Biologika GmbH

                            Germany arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VLA2001,CPG ODN 1018,Aluminium Hydroxide

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Valneva

                            Deal Size : $39.9 million

                            Deal Type : Termination

                            DEALS_DEV arrow-down

                            Valneva and IDT Biologika Agree on Termination of their COVID-19 Collaboration

                            Details : VLA2001 is produced on Valneva’s established Vero-cell platform, leveraging technology. VLA2001 consists of inactivated whole virus particles of SARS-CoV-2 with high S-protein density, in combination with two adjuvants, alum and CpG 1018.

                            Brand Name : VLA2001

                            Molecule Type : Vaccine

                            Upfront Cash : $35.5 million

                            September 16, 2022

                            Lead Product(s) : VLA2001,CPG ODN 1018,Aluminium Hydroxide

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Valneva

                            Deal Size : $39.9 million

                            Deal Type : Termination

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            IDT Biologika GmbH

                            Germany arrow
                            Fi Europe 2024
                            Not Confirmed

                            IDT Biologika GmbH

                            Germany arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MVA-SARS-2-S vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Recipient : German Center for Infection Research

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            COVID-19 Vaccine Developed by German Research Group Fails in Early Trial

                            Details : A coronavirus vaccine, MVA-SARS-2-S vaccine, developed by the German Centre for Infection Research (DZIF) and vaccine maker IDT Biologika did not prompt the hoped-for immune reaction in early-stage testing on humans.

                            Brand Name : MVA-SARS-2-S vaccine

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            January 08, 2021

                            Lead Product(s) : MVA-SARS-2-S vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Recipient : German Center for Infection Research

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            IDT Biologika GmbH

                            Germany arrow
                            Fi Europe 2024
                            Not Confirmed

                            IDT Biologika GmbH

                            Germany arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MVA-SARS-2-S vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Germany Approves Third Trial of COVID-19 Vaccine Candidate

                            Details : The trial of the vaccine, which has been developed with the German Centre for Infection Research (DZIF), will be conducted on 30 participants aged between 18 and 55 who will receive two vaccinations at four-week intervals.

                            Brand Name : MVA-SARS-2-S vaccine

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            October 02, 2020

                            Lead Product(s) : MVA-SARS-2-S vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth